Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
MINERVA SURGICAL, INC. Minerva Surgical, Inc. Stock price
Equities
UTRS
US60343F2056
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1.957 USD | +4.65% | +13.12% | -56.20% | |
| Nov. 13 | Minerva Surgical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Nov. 13 | Earnings Flash (UTRS) MINERVA SURGICAL Reports Q3 Revenue $12M | MT |
Financials (USD)
| Sales 2023 * | 51.81 M | Sales 2024 * | 59.61 M | Capitalization | 16.60 M |
|---|---|---|---|---|---|
| Net income 2023 * | -32.00 M | Net income 2024 * | -28.00 M | EV / Sales 2023 * | 0,32x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 0,28x |
| P/E ratio 2023 * | -0,46x | P/E ratio 2024 * | -0,65x | Employees | 174 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 30.76% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.65% | ||
| 1 week | +13.12% | ||
| Current month | +4.65% | ||
| 1 month | -40.79% | ||
| 3 months | -52.85% | ||
| 6 months | -51.08% | ||
| Current year | -56.20% |
1 week
1.56
1.97
1 month
1.553.23
Current year
1.5514.00
1 year
1.5514.00
3 years
1.55207.40
5 years
1.55207.40
10 years
1.55207.40
| Managers | Title | Age | Since |
|---|---|---|---|
Todd Usen
CEO | Chief Executive Officer | - | Jan. 01 |
Joel R. Jung
DFI | Director of Finance/CFO | 65 | 2020 |
| Chief Tech/Sci/R&D Officer | 57 | 2010 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Uri Geiger
CHM | Chairman | 55 | Feb. 08 |
Ali Behbahani
BRD | Director/Board Member | 46 | 2011 |
Derrick Sung
BRD | Director/Board Member | 50 | 2022 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 1.957 | +4.65% | 15 234 |
| 23-11-30 | 1.870 | +19.87% | 136,898 |
| 23-11-29 | 1.560 | -4.88% | 16,379 |
| 23-11-28 | 1.640 | -1.20% | 15,820 |
| 23-11-27 | 1.660 | -4.05% | 8,171 |
Delayed Quote Nasdaq, December 01, 2023 at 11:34 am EST
More quotes
Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. It has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. It offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.
Calendar
2024-03-04
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.870USD
Average target price
3.000USD
Spread / Average Target
+60.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.20% | 17 M $ | |
| +21.73% | 113 B $ | |
| -6.67% | 11 294 M $ | |
| -47.38% | 9 213 M $ | |
| -41.61% | 4 290 M $ | |
| -8.06% | 2 837 M $ | |
| -5.61% | 2 700 M $ | |
| +7.49% | 2 678 M $ | |
| +19.37% | 2 352 M $ | |
| +9.49% | 2 044 M $ |
